GlassScriptPhysician profile
Lawrence David Kaplan
NPI 1104800572
$3,521.40
in general payments reported to CMS, 2019-2025
23 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 80% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $131 · 2021: $341 · 2022: $469 · 2023: $478 · 2024: $351 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.50 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $612.17 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $528.83 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.67 | 2019-2023 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Insmed, INC. | $384.23 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $256.47 | 2021-2025 | Winrevair |
| United Therapeutics Corporation | $253.53 | 2019-2023 | Tyvaso, Orenitram |
| Actelion Pharmaceuticals US, INC. | $241.59 | 2019-2023 | Uptravi, Opsumit |
| Genzyme Corporation | $153.13 | 2019-2025 | |
| Grifols USA, LLC | $110.63 | 2020-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $105.47 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $51.72 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $50.85 | 2019 | |
| Viatris Specialty LLC | $49.18 | 2025 | Yupelri |
| Amgen INC. | $47.16 | 2022-2023 | Tezspire |
| Genentech USA, INC. | $39.95 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $36.19 | 2025 | Ohtuvayre |
| Abbvie INC. | $30.39 | 2025 | |
| Philips North America LLC | $15.30 | 2022 | |
| Fisher & Paykel Healthcare INC | $14.83 | 2022 | |
| Gilead Sciences, INC. | $13.88 | 2021 | |
| Daiichi Sankyo INC. | $13.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.84 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.